Basic Information
| LncRNA/CircRNA Name | FOXD2-AS1 |
| Synonyms | NA |
| Region | GRCh38_1:47432133-47434641 |
| Ensemble | ENSG00000237424 |
| Refseq | NR_026878 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Western blot, in vitro knockdown, RIP |
| Sample | gastric cancer tissues, cell lines (BGC823, MGC803, AGS,SGC790, and MKN45) |
| Expression Pattern | up-regulated |
| Function Description | FOXD2-AS1 enrichment was upregulated markedly in GC and positively correlated with a large tumor size, a later pathologic stage, lymphatic metastasis, and a poor prognosis. Loss of FOXD2-AS1 function inhibited cell growth via inhibiting the cell cycle in GC, whereas upregulation of FOXD2-AS1 expression promoted cancer progression. The enhancer of zeste homolog 2 (EZH2) and lysine (K)-specific demethylase 1A (LSD1) proteins were found to serve as binding partners of FOXD2-AS1 and mediators of FOXD2-AS1 function. Mechanically, FOXD2-AS1 promoted GC tumorigenesis partly through EZH2 and LSD1 mediated EphB3 downregulation. FOXD2-AS1inhibited EphB3 transcrip-tion byFOXD2-AS1-mediated H3K27 methylation andH3K4 demethylation. |
| Pubmed ID | 29789713 |
| Year | 2018 |
| Title | Upregulation of the Long Noncoding RNA FOXD2-AS1 Promotes Carcinogenesis by Epigenetically Silencing EphB3 Through EZH2 and LSD1, and Predicts Poor Prognosis in Gastric Cancer |
External Links
| Links for FOXD2-AS1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |